Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating patient satisfaction, effectiveness, and safety of the drug Atezolizumab given by subcutaneous injection in people treated for certain cancers in routine healthcare settings. This observational study includes participants with specific types of lung cancer and hepatocellular carcinoma who receive Atezolizumab according to approved indications without altering their usual treatment plans. Participants are grouped into cohorts based on their diagnosis, including early-stage non-small cell lung cancer NSCLC after surgery and chemotherapy, metastatic NSCLC, extensive-stage small cell lung cancer ES-SCLC, and advanced or unresectable hepatocellular carcinoma HCC. The treatment with Atezolizumab is administered by the participants doctor independently of study participation. Throughout the study, participants report their satisfaction with the subcutaneous therapy using questionnaires at specific treatment cycles, and their quality of life is assessed by standardized tools. Researchers monitor survival outcomes and adverse events for up to approximately 3.5 years. The study captures real-world data on treatment experiences and monitors safety and effectiveness during routine clinical care.
Actively Recruiting
Researchers are collecting detailed information about patients with venous thromboembolism VTE to improve understanding of this condition, especially in groups often excluded from clinical trials such as pregnant women, elderly patients, and those with severe health issues. This observational registry aims to provide data that can help reduce death rates, recurrences of blood clots, bleeding problems, and arterial events related to VTE. This study gathers clinical details about each patient, including other health conditions, and tracks the type, dose, duration, and results of antithrombotic treatments over the first three months. The registry is accessible online to assist doctors in managing complex cases by comparing patient profiles and identifying those at higher risk of complications. Participants clinical status and treatment outcomes are recorded, focusing on recurrence of VTE, bleeding events, and mortality over a three-year period. The information supports the creation of predictive scores to help healthcare providers identify patients at higher risk. The study started in 2001 and plans to continue until 2027, with ongoing data collection and follow-up.
Actively Recruiting
Researchers are investigating whether certain host factors, including the variety and makeup of intestinal microbiota and genetic markers, are linked to a higher chance of recurrence of Clostridioides difficile infection CDI. The study aims to create a predictive tool that uses epidemiological, clinical, genetic, and microbiologic data to identify patients at greater risk of CDI coming back, within an optimized CDI management setting. This is a multicenter, prospective observational study involving adults diagnosed with CDI according to IDSA criteria. Participants will be part of a stewardship program designed to improve CDI management and enable early detection of CDI recurrence. Blood samples will be collected for genetic testing, and stool samples will be analyzed to study the intestinal microbiome. The study will monitor patients diagnosed with CDI over time without introducing experimental treatments. Throughout the study, researchers will assess the occurrence of CDI recurrence within the first 8 weeks after therapy ends and reinfection between 8 and 24 weeks post-therapy. They will also track hospital readmissions due to CDI during the 24 weeks following treatment completion. Data will be analyzed to identify predictors of recurrence, and the predictive tools accuracy will be evaluated. Participants may expect periodic monitoring as part of the study lasting until December 2029.
Actively Recruiting
This research aims to translate, culturally adapt, and validate the Korean KOQUSS-40 quality of life questionnaire into Spanish, creating the SPQUSS-41 tool. It focuses on patients who have undergone curative surgery for gastric cancer, addressing the significant impact such surgery has on quality of life, including gastrointestinal symptoms and emotional distress. The goal is to provide a specific and reliable measure for evaluating quality of life in clinical trials and patient care. The study is designed as a prospective, multicenter observational cohort under Spains EURECCA Esophagogastric Cancer Project. It includes two phases development and validation. In the development phase, the questionnaire will be translated, reviewed by experts, pre-tested with 20 patients, and pilot tested with 85 patients. The validation phase involves administering the final questionnaire to at least 410 patients and conducting a retest after 30 days to assess reliability, alongside other quality of life questionnaires. Participants will be adults over 18 years old, between 1 month and 5 years after curative gastric cancer surgery. Data on demographics, surgery details, and treatments will be collected and recorded securely. Researchers will assess the questionnaires validity, internal consistency, and test-retest reliability using statistical methods. The study is expected to last 1 to 2 years, involving multiple centers, with results to improve quality of life assessment and patient-clinician communication.
Actively Recruiting
Researchers are evaluating whether the medicine BI 1291583 can help adults and adolescents aged 12 to under 18 who have bronchiectasis and experience flare-ups, also called exacerbations. This Phase III randomized, double-blind, placebo-controlled study aims to assess the medicines safety, tolerability, and effect on reducing flare-ups in people with this condition. Participants are randomly assigned to one of two groups. One group takes BI 1291583 tablets, and the other takes placebo tablets that look the same but contain no active medicine. They take one tablet daily for up to 76 weeks, or about 1 year and 6 months. The study includes up to 10 in-person visits and around 13 phone calls with study staff during this time. During the study, participants regularly complete a symptom diary on a smartphone about their bronchiectasis. Study doctors monitor participants health, check for flare-ups, and record any unwanted effects. The main outcome measured is the annual rate of pulmonary exacerbations up to week 76, with other assessments including lung function tests and quality of life questionnaires. Participants stay in the study for up to 1 year and 8 months in total.